Results 201 to 210 of about 39,064 (303)

Accelerating innovation and ensuring the thoughtful withdrawal of lifeline medicines for people living with diabetes in Asia

Journal of Diabetes Investigation, Volume 16, Issue 7, Page 1147-1150, July 2025.
Coordinated regional action is urgently needed to safeguard insulin access in Asia amid global product realignment. This editorial emphasizes the ethical imperative and policy frameworks required to balance innovation with equitable, uninterrupted diabetes care.
Yutaka Seino, Daisuke Yabe, Sung Hee Choi, Chih‐Cheng Hsu, Chien‐Ning Huang, Altaisaikhan Khasag, Kathryn Tan, Kohjiro Ueki, Yuichiro Yamada, Zhanay A Akanov, Takashi Kadowaki   +10 more
wiley   +1 more source

The role of biosimilars in the treatment of rheumatic diseases [PDF]

, 2012
Thomas Dörner, Vibeke Strand, Gilberto Castañeda‐Hernández, Gianfranco Ferraccioli, John D. Isaacs, Tore K Kvien, E. Martín‐Mola, Thomas Mittendorf, Josef S Smolen, Gerd R Burmester   +9 more
openalex   +1 more source

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. [PDF]

Clin Ophthalmol
Aljuhani HS, Hubayni RA, Qedair J, Bukhari ZM, Alzahrani A, Bawazir RO, Badghaish OS, Alqahtani F.   +7 more
europepmc   +1 more source

Biosimilars: Company Strategies to Capture Value from the Biologics Market [PDF]

, 2012
Bruno Calo-Fernández, J. L. Martínez-Hurtado   +1 more
openalex   +1 more source

Effectiveness of rituximab and biosimilar rituximab in untreated diffuse large B‐cell lymphoma, a Danish population‐based analysis

British Journal of Haematology, Volume 207, Issue 1, Page 270-272, July 2025.
Amal Haujir, Michael Tøstesen, Tarec Christoffer El‐Galaly, Thomas Stauffer Larsen, Jørn Starklint, Christian Bjørn Poulsen, Pär Lars Josefsson, Erik Clasen‐Linde, Michael Pedersen, Andriette Dessau‐Arp, Michael Roost Clausen, Judit Mészáros Jørgensen   +11 more
wiley   +1 more source

Real-world familiarity with US biosimilar regulatory guidelines and interchangeability state laws among pharmacists and physicians treating immunological disorders. [PDF]

J Manag Care Spec Pharm
Ling YL, Gentile D, Kotomale A, Sharpe JA, Geli D, Gruben D, Omary C, Brackin C, Bailey M.   +8 more
europepmc   +1 more source

Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association

, 2011
B. E. Shaw, Dennis L. Confer, William Ying Khee Hwang, Derwood Pamphilon, Michael A. Pulsipher   +4 more
openalex   +2 more sources

Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings. [PDF]

BioDrugs
Kvien TK, Betteridge N, Brückmann I, Bodenmüller W, Bryn G, Danese S, Gonçalves J, Maravic Z, Thorne C, Wingate L, Cornes P.   +10 more
europepmc   +1 more source

Pharmacovigilance of biosimilars: challenges and possible solutions [PDF]

, 2012
Thijs J. Giezen
openalex   +1 more source

Sandoz Inc. v. Amgen Inc.: Removing Barriers to Market Access for Biosimilar Manufacturers [PDF]

, 2019
Koya, Moyosore O.
core   +1 more source